The molecular programme of tumour reversion: the steps beyond malignant transformation
Authors:
- 30 January 2009
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 9 (3) , 206-216
Abstract
How cells become malignant has preoccupied scientists for over a century. However, the converse question is also valid: are tumour cells capable of reverting from their malignant state? Askanazy's studies in 1907 indicated that teratoma cells could differentiate into normal somatic tissues and current evidence indicates that some tumour cells have acquired the molecular circuitry that results in the negation of chromosomal instability, translocations, oncogene activation and loss of tumour suppressor genes. Studying these extremely rare events of tumour reversion and deciphering these pathways, which involve SIAH1, presenilin 1, TSAP6 and translationally controlled tumour protein (TCTP), could lead to new avenues in cancer treatment.Keywords
This publication has 152 references indexed in Scilit:
- Microarray analysis of perichondral and reserve growth plate zones identifies differential gene expressions and signal pathwaysBone, 2008
- TCTP protects from apoptotic cell death by antagonizing bax functionCell Death & Differentiation, 2008
- NUMB controls p53 tumour suppressor activityNature, 2008
- Tpt1 Activates Transcription of oct4 and nanog in Transplanted Somatic NucleiCurrent Biology, 2007
- Inactivating mutations of the Siah-1 gene in gastric cancerOncogene, 2004
- Cancer genes and the pathways they controlNature Medicine, 2004
- Numb Is an Endocytic ProteinJournal of Cell Biology, 2000
- Notch Signaling: Cell Fate Control and Signal Integration in DevelopmentScience, 1999
- Control of Daughter Cell Fates during Asymmetric Division: Interaction of Numb and NotchNeuron, 1996
- Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease geneNature, 1995